NVID International, Inc. Closes Agreements With Innovative Medical Services.

Business Editors

CLEARWATER, Fla.--(BUSINESS WIRE)--Jan. 14, 2000

NVID International, Inc. (OTC BB:NVID) announced today that it has closed the definitive agreements for Axenohl(TM) and the Reservoir Metering System ("RMS") with Innovative Medical Services (NASDAQ:PURE) of El Cajon, California. The disinfection foundation of Axenohl(TM) and RMS are derived from a form of silver and / or silver compounds, which controls over 650 different microbes as cited by the National Academy of Sciences.

The Axenohl(TM) and RMS agreements grant Innovative Medical Services specific marketing and licensing rights for Axenohl(TM) and the RMS silver ionization technology. NVID has received up-front licensing fees for both Axenohl(TM) and RMS, and will receive royalties on all Axenohl(TM) and RMS sales generated by Innovative Medical Services per previous press releases.

Axenohl(TM) is NVID's patent-pending, non-toxic aqueous disinfectant that poses no toxicity to humans or animals. Based upon proprietary ionization stabilization technology, Axenohl(TM) does not include the use of traditional disinfectants such as quaternary ammonium salts, phenols, glutaraldehyde, chlorine or bromine compounds. The technology enhances the disinfection properties of halogens (chlorine) at reduced levels and is positioned to be a cost effective, stand alone alternative to halogens in many markets where conventional disinfection methodologies are being employed. The disinfection efficacy of Axenohl(TM) has been well documented by independent testing laboratories. Axenohl(TM) eliminates the following test organism strains all within one minute and 99.9999% efficacy (complete kill): Pseudomonas aeruginosa ATCC 15422, Staphylococcus aureus ATCC 6538, Salmonella cholerasuis ATCC 10708, E. Coli ATCC 0157:H7, Listeria monocytogenes ATCC 11543, Entrococcus facium ATCC 11543, Rhinovirus (common colds) Rotavirus, (infectious diarrhea). The Axenohl(TM) International Patent Application was published by the World Intellectual Property Organization on April 22, 1999 under publication Number WO 99/18790 and is available for public inspection.

A multi-year licensing arrangement for Axenohl(TM) is in place with Innovative Medical Services for the following markets:

1. Healthcare Market 2. Point-of-Use / Point-of-Entry Market 3. Food Processing Market 4. Dental Water Lines

Innovative Medical Services is committed to two world-class Axenohl(TM) research projects that include: The U.S. Department of Agriculture's (Agricultural Research Service / Athens, GA) has signed a Trust Fund Cooperative Agreement (Agreement No. 58-6612-0-203), and has committed research dollars for one year specifically to evaluate and identify Axenohl's efficacy and applications for food processing (poultry) disinfection issues. This research project fits the goals of the USDA, which is committed to evaluate disinfection technologies that promise to be more efficacious, cost-effective and environmentally friendly than traditional disinfectants.

Dr. Richard I. Karpay DDS, MPH and Chairman of the American Dental Association ("ADA") subcommittee on air and water lines will conduct approximately four months of research to evaluate the disinfection effectiveness of Axenohl(TM) for dental unit waterlines. The ADA recently has set new goals for dental waterlines, which state that acceptable biologic quality of the water should be less than 200 CFU/mL. The State of California has taken the lead and already adopted the less than 200 CFU/mL guideline established by the ADA. Both research projects are projected to commence in February 2000.

Additional research just completed in November by EPL Bio-Analytical Services of Harristown, IL and Key Laboratory Services of Decatur, IL proves the disinfection efficacy of Axenohl(TM) against Vancomycin Resistant Enterococcus ("VRE"). VRE is an Enteroccocus organism that has become resistant to typical antibiotics frequently used in hospitals. VRE is usually spread by direct contact with hands, environmental surfaces or medical equipment that has been contaminated. Axenohl(TM) was 99.9999 effective against VRE within one minute at the low level of 1.18 ppm. The results of this research have been submitted to the FDA as part of a broader submittal package that seeks FDA compliance on 14 products for both human and veterinary usage.

In addition, EPL Bio-Analytical has submitted the Axenohl(TM) research data package for EPA registration purposes within the last sixty days. NVID is optimistic that an EPA registration number for Axenohl(TM) will be granted within the second quarter of 2000, if not sooner.

The RMS ionization system is a non-halogen (chlorine) disinfection system that effectively treats large volumes of water with ionic silver. Designed to be a cost effective alternative to the use of halogens for water disinfection in either single pass or re-circulating systems, RMS technology delivers ionic silver using proprietary assayed electrodes. The ions are metered into the process water by dosing pumps based upon flow rates to ensure a precise dosage of ions. Generation of the ion concentrate is produced off-line by the RMS without utilizing the process water, enabling the equipment to produce ions more effectively and efficiently than conventional ionization systems. NVID was granted approval by the Director General of Environmental Health for residential and commercial drinking water disinfection in Mexico in December of 1998. An RMS system was installed in Punta Mita, Mexico for disinfecting municipal drinking water in October of 1999, in which NVID has been working with one of the largest company's in Mexico City on this installation to evaluate the technology for future projects.

About Innovative Medical Services

Innovative Medical Services, based in El Cajon, California, manufactures and markets water purification, measuring, and dispensing equipment used in pharmacies to reconstitute oral antibiotic suspensions, and residential drinking water filtration systems used in consumer markets. The Company's customer base for its Fillmaster(R) pharmacy systems includes Wal-Mart, Walgreen's, American Stores, Eckerd, Kroger, Fred Meyer, Target and CVS. The Company's Nutripure(R) line of residential water systems includes a residential reverse osmosis water system available as either a convenient, compact unit easily installed beneath the sink, or as an attractive countertop appliance requiring no installation. Brand recognition for the Nutripure products is driven by the new Nutripure 2000 countertop water filtration system. Nutripure 2000 competes with PUR(R), Brita(R) and Culligan(R) products. The Company's products can be purchased online form IMS' Yahoo(R) Store at stores.yahoo.com/nutripure or from its web site at www.imspure.com.

About NVID International

NVID International, Inc. based in Clearwater, Florida manufactures and markets patent and patent-pending, proprietary ionization disinfection technologies that substantially reduce or replace traditional disinfectants such as chlorine, quaternary ammonium salts, phenols and glutaradehyde. Axenohl(TM) is NVID's non-toxic disinfectant that is based upon ionization stabilization technology that poses no toxicity to humans or mammals. Target markets include: hospital water systems, POU / POE commercial, municipal, and residential drinking water, FDA compliant consumer products for human and veterinary usage, pools and spas, cisterns / wells, horticulture, and food processing applications.

Except for historical information contained herein, the matters discussed in this news release are forward-looking statements with respect to the future activities of the Company. These forward-looking statements by their vary nature involve risks and uncertainties and represent the Company's judgement as of the date of this release. NVID International, Inc. and Aqua Bio Technologies, Inc. can be reached at: